Romosozumab 105mg/1.17mL Injection — Sclerostin Inhibitor for Osteoporosis in Postmenopausal Women at High Fracture Risk
Evenity® (Romosozumab) — Dual-Action Bone-Building Therapy for Osteoporosis
A Sourcing Guide for Hospitals and Endocrinology Clinics
Evenity® (Romosozumab) is a humanised monoclonal antibody indicated, according to its approved prescribing information, for the treatment of osteoporosis in postmenopausal women at high risk of fracture, defined as a history of osteoporotic fracture or multiple risk factors for fracture, and in patients who have failed or are intolerant of other available osteoporosis therapy. As with all osteoporosis therapies, the decision to prescribe Evenity, including cardiovascular risk assessment, rests entirely with the treating physician, in accordance with the approved label. This page provides sourcing and procurement information for hospitals and pharmacies, not clinical or treatment guidance.
As both a trusted medicine distributor in Delhi and a licensed pharmaceutical distributor in Delhi, A.K. Pharma supplies genuine Evenity (Romosozumab) 105mg/1.17mL pre-filled syringes to hospitals, endocrinology clinics, orthopaedic centres, and pharmacies across India. Hospitals managing broader bone health caseloads can also source companion medicines through A.K. Pharma’s full product range.
Evenity contains Romosozumab, a humanised IgG2 monoclonal antibody that binds to and inhibits sclerostin, a protein produced by osteocytes that normally suppresses bone formation.
Sclerostin’s Role in Bone Remodelling:
According to published endocrinology literature, sclerostin acts as a natural brake on osteoblast activity, limiting new bone formation as part of the body’s normal bone remodelling regulation. In osteoporosis, this braking effect, combined with age-related and hormonal changes, contributes to a net loss of bone density over time as resorption outpaces formation.
Romosozumab’s Dual Mechanism: By binding to and inhibiting sclerostin, Romosozumab increases bone formation by stimulating osteoblastic activity, and, to a lesser extent, decreases bone resorption, according to the manufacturer’s prescribing information. This dual action — described as “anabolic and antiresorptive” — distinguishes Romosozumab from purely antiresorptive agents such as Denorange (Denosumab) and Prolia (Denosumab), which act primarily by suppressing bone resorption rather than actively stimulating new bone formation.
Full prescribing information is available at the FDA label for Romosozumab, with additional background on osteoporosis pathophysiology available via the International Osteoporosis Foundation and the National Institute of Arthritis and Musculoskeletal and Skin Diseases.
FRAME Trial (Romosozumab vs Placebo in Postmenopausal Osteoporosis)
Published in the New England Journal of Medicine (2016), the pivotal FRAME trial randomised 7,180 postmenopausal women with osteoporosis to Romosozumab or placebo for 12 months, followed by Denosumab in both groups for an additional 12 months. Key findings included significantly reduced vertebral fracture risk with Romosozumab at both 12 and 24 months, along with substantial increases in bone mineral density at the lumbar spine and total hip.
ARCH Trial (Romosozumab vs Alendronate in High-Risk Postmenopausal Osteoporosis)
Published in the New England Journal of Medicine (2017), the ARCH trial compared Romosozumab followed by Alendronate against Alendronate alone in postmenopausal women with osteoporosis and a prior fragility fracture. Romosozumab-treated patients had a significantly lower risk of new vertebral, clinical, and hip fractures compared to those receiving Alendronate alone, though a numerical imbalance in serious cardiovascular events was observed during the Romosozumab treatment phase, which became a key part of the medicine’s safety labelling.
For broader clinical guidance on osteoporosis management, the American Society for Bone and Mineral Research (ASBMR) and the American College of Rheumatology publish ongoing clinical guidance.
Evenity is supplied as:
| Presentation | Strength |
|---|---|
| Evenity Pre-Filled Syringe | 105mg/1.17mL, single-use |
Standard Dosing (per approved prescribing information):
| Detail | Regimen |
|---|---|
| Monthly dose | 210mg (two consecutive 105mg subcutaneous injections) |
| Treatment duration | Limited to 12 monthly doses |
| Supplementation | Calcium and vitamin D supplementation required throughout treatment |
Treatment duration is specifically limited to 12 monthly doses, per the approved label, since the anabolic bone-formation effect diminishes with continued use beyond this period.
Osteoporosis in Postmenopausal Women at High Fracture Risk:
Following the 12-month Evenity treatment course, continued therapy with an antiresorptive agent is typically considered to help maintain the bone density gains achieved, per the approved prescribing information.
For detailed indication information refer to MedlinePlus Osteoporosis and the National Osteoporosis Foundation.
Dual Anabolic and Antiresorptive Action
Evenity’s mechanism both stimulates new bone formation and modestly reduces bone resorption, distinguishing it from purely antiresorptive agents in the bone health treatment landscape.
Rapid Onset of Effect
According to published clinical data, Romosozumab’s bone-building effect can be observed within approximately 2 weeks of the first injection, with substantial bone mineral density gains demonstrated over the 12-month treatment course.
Substantial Fracture Risk Reduction
The FRAME and ARCH trials demonstrated significant reductions in vertebral, clinical, and hip fracture risk, supporting Evenity’s role in high-risk osteoporosis populations.
Option for Patients Failing Other Therapies
Evenity provides a treatment pathway for patients who have not responded adequately to, or cannot tolerate, other available osteoporosis therapies.
Dosing of Evenity is determined by the prescribing physician according to the approved label. General administration information from the manufacturer’s prescribing information includes:
Monitoring (per manufacturer prescribing information):
Full dosing guidelines are available in the manufacturer’s official prescribing information and should always be followed exactly as directed by the treating physician.
Evenity is prescribed by endocrinologists, rheumatologists, and orthopaedic specialists for:
Evenity is prescribed by specialists managing postmenopausal osteoporosis. A.K. Pharma supplies Evenity to hospitals and endocrinology clinics across Delhi and India.
Common side effects reported in clinical trials include joint pain, headache, and injection site pain or irritation.
Serious side effects include:
Cardiovascular Risk: A Boxed Warning addresses the potential increased risk of myocardial infarction, stroke, and cardiovascular death observed in clinical trials. Evenity should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year, per the approved prescribing information.
Hypocalcaemia: Evenity should not be used in patients with pre-existing hypocalcaemia, which must be corrected before treatment initiation.
Osteonecrosis of the Jaw: A rare but recognised risk associated with bone-active therapies; dental assessment may be considered for patients with risk factors.
Atypical Femoral Fractures: Rare fractures of the femoral shaft have been reported with bone-active therapies generally; patients should be counselled to report new or unusual thigh, hip, or groin pain.
Full side effect information is available at FDA Romosozumab Safety Information.
As a responsible medicine distributor in Delhi, A.K. Pharma stores all bone health biologics including Evenity under manufacturer-recommended cold chain conditions ensuring product integrity for every supply.
Evenity (Romosozumab) is manufactured by Amgen Inc. and UCB. Romosozumab received FDA approval in April 2019 for osteoporosis treatment in postmenopausal women at high risk of fracture. A.K. Pharma supplies only genuine Evenity sourced from authorised distributors. Learn more about Amgen’s bone health portfolio directly from the manufacturer.
Q. What is Evenity used for?
Evenity (Romosozumab) is used to treat osteoporosis in postmenopausal women at high risk of fracture, including those with a history of osteoporotic fracture or who have failed other osteoporosis therapies.
Q. What is the generic name and strength of Evenity?
The generic name of Evenity is Romosozumab, supplied as 105mg/1.17mL pre-filled syringes, manufactured by Amgen Inc. and UCB.
Q. How is Evenity different from Prolia or Denorange?
Evenity has a dual anabolic and antiresorptive mechanism, stimulating new bone formation while modestly reducing bone resorption. Prolia and Denorange (both Denosumab) work primarily by inhibiting RANKL to reduce bone resorption, without the same bone-forming effect.
Q. Why is Evenity treatment limited to 12 monthly doses?
Clinical data shows that Romosozumab’s bone-forming effect diminishes with continued use beyond 12 months, which is why treatment duration is limited per the approved label, with continued antiresorptive therapy typically considered afterward.
Q. Why does Evenity carry a cardiovascular Boxed Warning?
Clinical trial data showed a numerical imbalance in cardiovascular events, including myocardial infarction and stroke, in patients receiving Romosozumab compared to comparator therapy, which is why it should not be initiated in patients with a myocardial infarction or stroke within the preceding year.
Q. Is Evenity available in India?
Evenity can be supplied to hospitals and endocrinology clinics across India through licensed pharmaceutical distributors. Contact A.K. Pharma — medicine distributor in Delhi and pharmaceutical distributor in Delhi — for availability and pricing.
Q. What is the price of Evenity in India?
Evenity price in India varies by order quantity. Contact A.K. Pharma at 011 4172 6999 or WhatsApp +91 9810034827 for current pricing and bulk supply rates.
Q. How to order Evenity from A.K. Pharma?
You can request a quote directly from this page, call us at 011 4172 6999, or WhatsApp us at +91 9810034827 with your requirements and we will respond promptly.
Q. Does A.K. Pharma supply Evenity in bulk?
Yes. A.K. Pharma supplies Evenity in bulk to hospitals and endocrinology clinics across Delhi and India.
📍 E-2/257A, 2nd Floor, Shastri Nagar, New Delhi 110052
📞 011 4172 6999
📱 WhatsApp: +91 9810034827
🌐 akpharma.in
Disclaimer: This page is intended for informational and sourcing/procurement purposes only and does not constitute medical or clinical advice. All treatment decisions, including drug selection and dosing, should be made by a qualified healthcare professional in accordance with the approved prescribing information. A.K. Pharma is a licensed medicine distributor and does not provide clinical guidance.
